

IPW
TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
CSO-0001-P

In Re Application Of: Sophie Chen

FEB 21 2006

PATENT & TRADEMARK OFFICE

Examiner

delacroix

Customer No.

23413

Group Art Unit

1614

Confirmation No.

2036

Title: BOTANICAL EXTRACT COMPOSITIONS AND METHODS OF USE

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.96 or 1.97(c))

Docket No.
CSO-0001-P

In Re Application of: Sophie Chen

FEB 21 2006
PATENT & TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCE

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/647,458	August 1, 2003	delacroix	23413	1614	2036

Title: BOTANICAL EXTRACT COMPOSITIONS AND METHODS OF USE

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 06-1130 as described below.
 - Charge the amount of _____
 - Credit any overpayment.
 - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

February 17, 2006

(Date)

Signature of Person Mailing Correspondence

Tracy A. Axiak

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Karen A. LeCuyer
Signature

Dated: February 17, 2006

Karen A. LeCuyer
Registration No. 51,928
Phone No. 860-286-2929

CC:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sophie Chen) Group Art Unit: 1614
Serial No.: 10/647,458)
Filing Date: August 1, 2003) Examiner: NYA
For: BOTANICAL EXTRACT)
COMPOSITIONS AND METHODS)
OF USE)



INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose, submitted herewith is form PTO-A820 (PTO-1449) listing publication(s) of which those designated by 37 CFR § 1.56 are aware. Copies of the non-United States patents or published applications are enclosed.


The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made, or an admission that the information cited is, or is considered to be, material to patentability.

Respectfully submitted,

CANTOR COLBURN LLP

By: Karen A. LeCuyer
Karen A. LeCuyer Ph.D.
Registration No. 51,928

Date: February 17, 2006
Customer No. 23,413
(860) 286-2929

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> FEB 21 2006 			Docket Number (Optional) CSO-0001-P		Application Number 10/647,458		
			Applicant(s) Sophie Chen				
			Filing Date August 1, 2003		Group Art Unit 1614		
			U.S. PATENT DOCUMENTS				
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
U.S. PATENT APPLICATION PUBLICATIONS							
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation
							<input type="checkbox"/> YES
							<input type="checkbox"/> NO
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
		Ikemoto, et al. "ANTITUMOR EFFECTS OF Scutellariae radix AND ITS COMPONENTS BAICALEIN, BAICALIN, AND WOGONIN ON BLADDER CANCER CELL LINES". Basic Science. Urology. Vol. 55. No. 6. 2000. pp. 951-955					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							